In the early months of the pandemic, when much of the economy was idling, an unusual silence fell over another […]
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs Read Post »
Off-patent drugs represent one of the most systematically underexploited categories in the pharmaceutical IP landscape. Their pharmacology is known. Their
A technically dense, data-grounded analysis of repurposing economics, IP valuation, regulatory pathways, computational platforms, and lifecycle management tactics for existing
Drug Repurposing: The Definitive Strategic Guide Read Post »
Why Patents Are the Wrong Starting Point Most analysts open a pharma investment thesis by pulling Orange Book listings and
What Actually Drives Pharma Returns: 10 Non-Patent Factors Every Investor Needs to Model Read Post »
1. Executive Summary FDA approval of a generic drug is a regulatory milestone, not a commercial launch date. The gap
Part I: US Pharmaceutical Market — Scale, Structural Drivers, and the 2025 Inflection Point Market Size Reality Check: Reconciling Competing
Introduction: The $2 Billion Data Problem Start with the math. A new drug costs roughly $2 billion and a decade
Chemical Databases in Drug Discovery: The Complete IP and R&D Intelligence Playbook Read Post »
The complete guide for pharma IP teams, portfolio managers, R&D leads, and institutional investors on extracting maximum asset value from
Off-Label Drugs and Repurposing: The Full IP, Regulatory, and Commercial Playbook Read Post »
Check out this Bloomberg Law article where DrugPatentWatch shows how the number of patent challenges is increasing, while the number of
DrugPatentWatch and Bloomberg: Are there too many generic patent challenges? Read Post »
Get fresh news and insights, drug patent expirations & more…
